|

Neoadjuvant toripalimab plus celecoxib for 6 cycles Clinical Trials

1 actively recruiting trial

Also known as: Celecoxib, Toripalimab

Pipeline

Phase 2: 1

Top Sponsors

  • Sun Yat-sen University1

Indications

  • Microsatellite Instability-high (MSI-H)1
  • Mismatch Repair-deficient (dMMR)1
  • Colorectal Cancer1
  • Neoadjuvant Therapy1
  • Cancer1

Other1 trial

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.